SEC Form 4	
------------	--

FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number:

STATEMENT	OF	CHA

ANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1 0			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>y L</u>			X Director	10% Owner					
st) (Midd		nth/Day/Year)	X Officer (give title below)	Other (specify below)					
ET	04/01/2024		President and CEO						
	4. If Amendment, Date of Original F	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Chec							
		Lin	· · · · · · · · · · · · · · · · · · ·						
0854			X Form filed by One Reporting Person Form filed by More than One Reporting Person						
ate) (Zip)	Rule 10b5-1(c) Transa	action Indication							
	Check this box to indicate that a t satisfy the affirmative defense con	ransaction was made pursuant to a con nditions of Rule 10b5-1(c). See Instruct	ontract, instruction or written plan tha stion 10.	t is intended to					
	ET 08542	y_L AMICUS THERAPEUT sst) (Middle) ET 3. Date of Earliest Transaction (Mo 04/01/2024 08542 4. If Amendment, Date of Original F 08542 Rule 10b5-1(c) Transaction (V) V Check this box to indicate that a to indicate the tat a to indicate the tag in the indicate the tag in the indicate the indicate the tag in the indicate the	AMICUS THERAPEUTICS, INC. [FOLD] (C y_L 3. Date of Earliest Transaction (Month/Day/Year) (C 3. Date of Earliest Transaction (Month/Day/Year) (C 04/01/2024 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Lir 08542 Rule 10b5-1(c) Transaction Indication V Check this box to indicate that a transaction was made pursuant to a co	AMICUS THERAPEUTICS, INC. [FOLD] (Check all applicable) y_L 3. Date of Earliest Transaction (Month/Day/Year) (Check all applicable) 3. Date of Earliest Transaction (Month/Day/Year) Officer (give title below) 04/01/2024 President and Clever 08542 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Clever) x Form filed by One Reporti Form filed by More than Clever ate) (Zip) (Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
		Code V		v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	04/01/2024		М		7,500	A	\$8.61	894,154	D	
Common Stock	04/01/2024		S		7,500	D	\$ 11.6661 ⁽¹⁾	886,654	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(e.g., puis, cans, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Transaction Code (Instr. 8)		umber ivative urities uired or oosed O) tr. 3, 4 5)	Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (right to buy)	\$8.61	04/01/2024		М			7,500	(2)	01/02/2025	Common Stock	7,500	\$0.0	60,000	D	

Explanation of Responses:

1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$11.53 to \$11.76 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. All of the options were fully vested and exercisable as of the transaction date.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2023.

/s/ Christian Formica
Attorney-in-Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<u>a</u>,

Date

04/03/2024

